ARTA
FOMX

A.R.T. Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

A.R.T. Advisors’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,701
Closed -$40K – 1780
2019
Q1 		$40K Sell
10,701
-12,471
-54% -$46.7K ﹤0.01% 1231
2018
Q4 		$83K Buy
+23,172
New +$101K 0.01% 1178
2018
Q2 		– Sell
-20,321
Closed -$104K – 1926
2018
Q1 		$104K Buy
+20,321
New +$122K ﹤0.01% 1351
2017
Q3 		– Sell
-18,308
Closed -$84K – 1835
2017
Q2 		$84K Buy
+18,308
New +$81.7K ﹤0.01% 1268
2016
Q2 		– Sell
-13,440
Closed -$87K – 1765
2016
Q1 		$87K Sell
13,440
-17,700
-57% -$114K ﹤0.01% 1262
2015
Q4 		$252K Buy
+31,140
New +$233K 0.01% 1121
2015
Q3 		– Sell
-37,339
Closed -$382K – 1725
2015
Q2 		$382K Buy
37,339
+24,008
+180% +$265K 0.01% 1099
2015
Q1 		$123K Sell
13,331
-573
-4% -$5.13K ﹤0.01% 1295
2014
Q4 		$97K Buy
+13,904
New +$79.6K ﹤0.01% 1306

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

A.R.T. Advisors's FOMX Position: Q2 2019 in Review

A.R.T. Advisors sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2019, closing a stake of 10,701 shares — an estimated $40K sold.

A.R.T. Advisors first reported a position in FOMX in Q4 2014 and held it in 9 quarters. The position peaked at $382K in Q2 2015. 58 funds tracked by Wall St. Rank hold FOMX as of Q2 2019.

  • A.R.T. Advisors reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 10,701 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2019, an estimated $40K.
  • A.R.T. Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2014 and held it in 9 quarters.
  • A.R.T. Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $382K in Q2 2015.
  • 58 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.